Advanced NSCLC: patients rank treatment side effects from bad to worst

  • Islam KM & al.
  • BMC Cancer
  • 27 Aug 2019

  • curated by Craig Hicks
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients with advanced-stage NSCLC rank shortness of breath, bleeding, and fatigue as the adverse effects of chemotherapy they would most like to avoid.

Why this matters

  • Coupling patient preferences and profiles of commonly used chemotherapy regimens could result in patient-centered treatment plans with better outcomes.

Study design

  • Researchers studied the treatment choices of patients with advanced-stage NSCLC (n=232; 55.6% men; 95.3% white) based on medical records and interviews.
  • Funding: Patient-Centered Outcomes Research Institute.

Key results

  • Before and after experiencing chemotherapy, patients selected the adverse effect they would most like to avoid:
    • Shortness of breath (before, 28.7%; after, 20.8%);
    • Unusual or increased bleeding (20.9%; 14.3%);
    • Decreased energy or excessive fatigue (11.9%; 25.6%);
    • Dizziness (10.8%; 10.7%);
    • A lot more expensive (8.4%; 9.5%);
    • Jaundice (8.4%; 7.7%);
    • More trips to clinic for treatment (7.2%; 7.1%);
    • Numbness or tingling (1.8%; 1.2%); and
    • Brittle nails (1.8%; 2.9%).

Limitations

  • Study data are not publicly available to protect patient confidentiality.
  • Checkpoint inhibitors were not an approved first-line treatment during the study.
  • Study results are limited to patients with advanced NSCLC.